Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
5.7
3.0
Journals
JCM
Special Issues
Clinical Application of Radiotherapy in Modern Oncology
share announcement

Clinical Application of Radiotherapy in Modern Oncology

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Oncology".

Deadline for manuscript submissions: 30 July 2025 | Viewed by 1356

Special Issue Editors

Dr. Lukas Käsmann

E-Mail Website
Guest Editor
Department of Radiation Oncology, Ludwig-Maximilian University of Munich, 81377 Munich, Germany
Interests: clinical trials; multimodal treatments; malignancies of the thoracic region; SCLC; NSCLC; translational research; radiation-induced side effects; applications
Dr. Fabian Weykamp

E-Mail Website
Guest Editor
1. Department of Radiation Oncology, Heidelberg University Hospital, 69120 Heidelberg, Germany
2. Clinical Cooperation Unit Radiation Oncology, German Cancer Research Center (DKFZ), 69120 Heidelberg, Germany
Interests: online adaptive radiotherapy; MR-guided radiotherapy; malignancies of the thoracic region; SCLC; NSCLC; hyperthermia therapy
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Radiotherapy (RT) is an integral part of modern cancer treatment besides surgery and systemic treatment, including targeted therapy and immune checkpoint inhibition. It can be used in the management of almost all cancers as a curative treatment for palliate symptoms or as a prophylactic treatment. Recent advances, including intensity-modulated RT, volumetric-modulated arc therapy, stereotactic body RT, adaptive RT, MR guidance and modern brachytherapy, have improved radiation targeting, thereby limiting the radiation exposure of healthy tissues.

This Special Issue will cover the following important topics regarding the application of RT in oncology. The topics of interest include, but not restricted to, the following: brain metastasis, bone metastasis, brain tumors, head and neck cancers, lung cancer, mesothelioma, thymoma, thymic carcinoma, breast cancer, prostate cancer and sarcoma.

We look forward to your contributions and advancing our collective knowledge about the role of radiotherapy in modern oncology.

Dr. Lukas Käsmann
Dr. Fabian Weykamp
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • brain metastasis
  • bone metastasis
  • brain tumors
  • head and neck cancers
  • thoracic oncology
  • breast cancer
  • prostate cancer
  • sarcoma

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

14 pages, 3388 KiB  
Article
Interstitial High-Dose-Rate Brachytherapy Combined with External Beam Radiation Therapy for Dose Escalation in the Primary Treatment of Locally Advanced, Non-Resectable Superior Sulcus (Pancoast) Tumors: Results of a Monocentric Retrospective Study
by Maria Neu, Klaus-Henning Kahl, Melina Körner, Renate Walter, Stephan Raab, Bertram Jehs, Lukas Käsmann, Vratislav Strnad, Georg Stüben and Nikolaos Balagiannis
J. Clin. Med. 2024, 13(24), 7550; https://doi.org/10.3390/jcm13247550 - 11 Dec 2024
Viewed by 886
Abstract
Objectives: To analyze the results of interstitial (IRT) high-dose-rate (HDR) brachytherapy (BT) in the primary treatment of patients with unresectable superior sulcus tumors (SST) combined with external beam radiotherapy (EBRT). Methods: Between 2013 and 2023, seven patients with unresectable SST were [...] Read more.
Objectives: To analyze the results of interstitial (IRT) high-dose-rate (HDR) brachytherapy (BT) in the primary treatment of patients with unresectable superior sulcus tumors (SST) combined with external beam radiotherapy (EBRT). Methods: Between 2013 and 2023, seven patients with unresectable SST were treated with combined BT and EBRT with or without concomitant chemotherapy. The patients’ median age was 64 years (range, 49–79 years) and median tumor volume was 146.8 cm3 (range, 29.3–242.3 cm3). A median BT dose of 8 Gray (Gy) (range, 5–10 Gy) was prescribed and delivered in a single fraction. A median EBRT dose of 54 Gy (range, 30–59 Gy) was prescribed and administered normofractionated (single dose: 1.8 Gy). Results: We report the results of seven patients with SST treated with combined BT and EBRT and followed for a median of 38 months. The overall clinical response rate was 83.33% with five out of six patients achieving local control, while one out of six (16.66%) showed local and general progression. No deaths were attributed to the treatment itself; rather, one patient died during the course of therapy as a result of systemic progression. The most common radiation-related adverse events were grade I–II fatigue and mild paresthesia. No severe toxicity (CTCAE ≥ III°) was observed with interstitial high-dose-rate (HDR) BT combined with EBRT. Conclusions: For patients with unresectable superior sulcus tumors, interstitial HDR BT in combination with EBRT is a feasible treatment option that offers the potential for local control and long-term survival. The findings of this study should be validated in a larger patient cohort. Full article
(This article belongs to the Special Issue Clinical Application of Radiotherapy in Modern Oncology)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-1
Back to TopTop